Fidelity

Capital Markets Gateway Inc. is a financial technology firm that specializes in modernizing the equity capital markets. Based in Chicago, Illinois, with additional locations in New York and Seattle, CMG offers a platform that provides real-time information and analytics to investors, underwriters, and issuers. Founded in 2015 and officially launched in 2017 by a team of experienced professionals, the platform enhances transparency and workflow efficiencies in capital raising activities. It enables users to monitor the capital raising landscape, conduct due diligence, and make informed investment decisions while facilitating collaboration between stakeholders. Currently, CMG's platform is utilized by over 100 buy-side firms and 10 investment banks, supporting a substantial amount of assets under management.

Celestial AI is a prominent artificial intelligence company that provides an advanced platform for users to efficiently create images, text, and presentations. Utilizing cutting-edge computer vision algorithms and natural language processing, the platform produces high-quality visual and textual content. Its intuitive design, combined with innovative features, facilitates easy content creation. Moreover, Celestial AI emphasizes intelligent data integration and prioritizes security, ensuring that users achieve impressive and reliable results.

Beta Technologies designs and develops electric aircraft and related systems, including propulsion, energy storage, and flight control technologies, with a focus on clean aviation. It builds integrated solutions to enable scalable electric flight, including charging infrastructure and pilot training tools for cargo, medical, passenger, and defense applications, and supports a self-sufficient eVTOL ecosystem that aims to improve access to vertical mobility for logistics and healthcare transport.

Waymo is a self-driving technology company dedicated to improving mobility. Established from Google's labs in 2009, Waymo aims to make transportation safer and easier by developing advanced software and sensor technologies. The company achieved the world's first fully self-driven trip on public roads in 2015, using cars without steering wheels or pedals. Today, Waymo continues to refine its technology through extensive simulation testing and real-world driving across multiple cities.

Frore Systems is a technology company based in San Jose, California, specializing in thermal management solutions for consumer devices. The company develops advanced cooling chips, specifically the AirJet® Mini and AirJet® Pro, which utilize piezoelectric MEMS technology to provide efficient and silent heat dissipation. These active cooling solutions significantly enhance device performance by outperforming traditional fan-based systems. With additional offices in Taiwan and South Korea, Frore Systems is positioned to impact the computing industry by enabling manufacturers to improve the thermal efficiency and performance of their devices.

CoreWeave develops a cloud infrastructure platform specializing in GPU-powered computing for blockchain initiatives. Its platform offers efficient scaling, tailored compute resources, and automated management tools to support advanced AI infrastructure.

SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company that develops a complete MLSoC platform combining hardware and software to enable high-performance, low-power machine learning inference on embedded edge devices. The platform supports traditional computing with ML inference, delivers push-button deployment and scaling at the edge, and adapts to various frameworks, networks, models, sensors, and modalities. It targets applications from computer vision to generative AI, offering improvements in performance and energy efficiency while enabling easy integration and secure operation for edge deployments.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Founded in 2017 and based in Boston, Lightmatter is an artificial intelligence hardware company that specializes in integrated optical technology. It designs photonic chips to enable data processing and communication through light signals, aiming to improve efficiency and scalability for AI data centers.

Vention is a cloud-based digital manufacturing platform that enables engineers and manufacturing professionals to design, order, and assemble custom factory equipment in days. It features a 3D Machine Builder with a library of modular structural, motion, and control components, including T-slot aluminum extrusion systems, and supports design, simulation, and ordering directly in a web browser. Its AI-enabled 3D constraints help optimize layouts and ensure feasible configurations, while the platform integrates design, programming, simulation, ordering, and commissioning in a single digital environment. Vention serves both experienced automation specialists and first-time designers, streamlining the creation of automated equipment for applications such as robot cells, tooling, conveyors, and other factory automation.

Founded in 2017, Coin Metrics provides comprehensive crypto financial intelligence. It offers network data, market data, indexes, and risk management solutions to institutions, empowering them with transparent and actionable insights for informed decision-making.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Menlo Micro, Inc. specializes in the design and development of electronic switches, particularly through its innovative Ideal Switch technology. This electromechanical switch is capable of handling both AC/DC and RF signals, making it suitable for a range of applications including high-power tunable resonators, filters, broadband power amplifier impedance matching, and electronically steerable antennas. The company's products are utilized in various industries, such as battery management, home automation, electronic vehicles, medical instrumentation, and the industrial Internet of Things, as well as in next generation 5G mobile networks. Founded in 2016 and headquartered in Irvine, California, Menlo Micro aims to enhance the efficiency and performance of advanced systems under high-stress conditions.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Founded in 2017, Astera Labs is a leading fabless semiconductor company based in Santa Clara, California. It specializes in designing and manufacturing purpose-built connectivity solutions for data-centric systems, focusing on robust PCIe connectivity. The company offers system-aware semiconductor integrated circuits, boards, and services to enhance performance in compute-intensive workloads.

The Veterinary Emergency Group operates a network of clinics specializing in pet emergency care. They provide urgent medical services, including diagnostics, surgery, and end-of-life care, ensuring availability on nights, weekends, and holidays.

Founded by JB Straubel in Nevada, Redwood Materials specializes in recycling lithium-ion batteries and electronics. It develops processes to extract and refine key materials like lithium, nickel, cobalt, and copper, creating a circular supply chain for electric vehicles and energy storage systems. The company aims to reduce environmental impact and lower production costs by recycling end-of-life products.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.

Tenstorrent designs and manufactures AI hardware and software for data processing and machine learning tasks. The company develops application-specific integrated circuit processors that enable scalable deep learning, with architectures designed to be software-programmable and adaptable from battery-powered IoT devices to cloud servers. Its processors target training and inference workloads, delivering computational performance for developers and researchers in artificial intelligence. Founded in 2016, Tenstorrent is based in Toronto with an additional office in Austin, Texas.

ASAPP, Inc. develops AI-Native products designed to address large-scale problems and systemic inefficiencies. Its flagship platform, ASAPP, enhances customer care and sales processes by providing agents with real-time guidance on appropriate responses and actions during customer interactions, whether through phone calls or digital messages. The platform continuously learns from each customer engagement, enabling it to adapt and improve without requiring extensive training or manual programming. ASAPP's solutions are utilized by major companies in the telecom, financial services, and travel sectors. Founded in 2014 and headquartered in New York, ASAPP also has locations in San Francisco, Mountain View, London, Buenos Aires, Ithaca, and Raleigh.

Moneytree is a fintech company that develops data aggregation platforms for personal finance management. Founded in Japan, it offers services across iOS, Android, and web platforms, with over 1.3 million users. Its proprietary platform, Moneytree LINK, serves enterprise clients including major accounting software vendors and banks.

Wasabi Technologies, Inc. is a Boston-based company that offers a cloud storage platform tailored for hybrid and multi-cloud media workflows. Founded in 2016, Wasabi provides hot storage solutions that utilize an Amazon S3 compatible API, enabling organizations to store and access data quickly, with average time-to-first-byte speeds under 15 milliseconds. The company's platform is designed to be simple and affordable, allowing customers to access unlimited data without complex pricing tiers or unpredictable egress fees. Wasabi's services cater to various industries, including media and entertainment, education, scientific research, law enforcement, healthcare, and energy. The company has gained recognition for its rapid growth and innovative approach to cloud storage, serving tens of thousands of customers worldwide.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Tenaya Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for heart disease and heart failure. It operates three product platforms: cellular regeneration, which aims to regenerate heart tissue by reprogramming cardiac fibroblasts into cardiomyocytes via delivery of proprietary transcription factors; gene therapy, which targets cardiac fibroblasts to deliver therapeutic payloads; and precision medicine, which enables personalized approaches to treat heart disease. Founded in 2016 and headquartered in South San Francisco, California, Tenaya seeks to address the underlying cellular pathologies of diseased myocardium with curative therapies that advance from discovery through development.

Founded in 2016, Pony.ai develops artificial intelligence software for autonomous mobility deployment, focusing on manufacturing automated vehicles and offering public-facing Robotaxi services. The company operates fully driverless robotaxis through the PonyPilot mobile app in major Chinese cities.

Rad Power Bikes LLC, based in Seattle, Washington, is North America's largest electric bike brand, incorporated in 2015. The company designs and manufactures electric bicycles suitable for both on and off-road use, offering feature-rich and affordable options tailored to individual needs. In addition to its bikes, Rad Power Bikes provides a range of accessories, including bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. Utilizing a direct-to-consumer sales model, the company has experienced rapid growth and aims to democratize electric biking, making energy-efficient transportation accessible and enjoyable for a wide audience. With a team of over 700 employees, Rad Power Bikes is committed to transforming the landscape of electric mobility.

Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Nuro is a technology company that develops autonomous driving technology and self-driving vehicles for local goods delivery. The company focuses on transforming local commerce by enabling merchants to deliver products directly to customers through autonomous delivery systems. Its autonomous driving platform is designed to work across vehicle types and to enable affordable, scalable fleet operations for goods transportation, reducing delivery times and offering a safer, contactless option for last-mile logistics.

Founded in 2016, Pony.ai develops artificial intelligence software for autonomous mobility deployment, focusing on manufacturing automated vehicles and offering public-facing Robotaxi services. The company operates fully driverless robotaxis through the PonyPilot mobile app in major Chinese cities.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.

Prelude Therapeutics is a clinical-stage company developing novel, orally bioavailable small-molecule therapies to target critical pathways in cancer cell growth and resistance. Its pipeline includes four candidates in clinical development targeting MCL1, CDK9, CDK4/6, and SMARCA2/BRM proteins.

Conformal Medical, Inc., established in 2016 and based in Nashua, New Hampshire, specializes in developing medical devices aimed at preventing stroke in patients with atrial fibrillation (AFib). The company's primary product is the CLAAS Technology, a solution designed to seal the left atrial appendage (LAA) in AFib patients. This technology forms part of their conformal left atrial appendage closure (LAAC) system.

Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

ApplyBoard is a technology company that simplifies the study abroad search, application, and acceptance process by connecting international students, recruitment partners, and educational institutions on a single platform, streamlining the journey from discovery to enrollment. The company operates globally, with headquarters in Kitchener, Ontario, and a dedicated office in Gurugram, India, reflecting its international reach.

Moneytree is a fintech company that develops data aggregation platforms for personal finance management. Founded in Japan, it offers services across iOS, Android, and web platforms, with over 1.3 million users. Its proprietary platform, Moneytree LINK, serves enterprise clients including major accounting software vendors and banks.

Alignment Healthcare is a healthcare organization focused on enhancing the healthcare experience for seniors through innovative Medicare Advantage plans. The company offers customized care and services, emphasizing clinical coordination and risk management. By marketing these plans directly to consumers, Alignment Healthcare allows seniors to choose how they receive healthcare coverage and services each year. The organization integrates a technology platform with a clinical model, facilitating care delivery across various channels, including phone, online, and in-person at doctors' offices or senior homes. This approach aims to improve health outcomes and provide a more consumer-centric healthcare experience.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Innophys Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in wearable robotics technology. The company designs, manufactures, and distributes innovative robotics equipment aimed at various industries. Its flagship product, the Muscle Suit®, utilizes artificial muscle technology to provide physical assistance, reducing strain during tasks such as lifting heavy objects or working in bent positions. The Muscle Suit® is recognized for its high quality and competitive pricing compared to other exoskeletons in the market. Innophys aims to expand its reach into the Asia Pacific, European, and North American markets, enhancing the ability of users to perform tasks independently and improve their quality of life.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit difficult growth and survival pathways, with an emphasis on RAS and mTOR signaling. Its portfolio includes RMC-4630, a SHP2 inhibitor, and programs addressing RAS-driven signaling via SOS1 and downstream 4EBP1/mTORC1 pathways. The company pursues a chemistry-based approach that assembles simple building blocks into drug-like, natural product-inspired structures, aiming to produce best-in-class candidates. It operates in collaboration with academic partners, including a licensing arrangement with the University of Illinois to extend its transformative synthesis technology, which underpins its drug discovery platform.

Allbirds, founded in 2015 and based in San Francisco, is an apparel and fashion company specializing in eco-friendly footwear. It manufactures and sells a variety of shoe styles for men, women, and children, including wool runners, tree runners, and loungers, using premium natural materials. The company's mission is to create sustainable footwear that combines comfort, good design, and environmental responsibility. Allbirds operates through its own stores, retail partners, and an online platform, with a significant portion of its revenue coming from the United States market.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

Cibus is a biotechnology company specializing in precision gene editing for agriculture, aimed at making farming more sustainable and profitable. The company has developed patented breeding technologies that facilitate precise and predictable modifications in plants without the integration of foreign genetic material. Its core innovation, the Rapid Trait Development System, combines crop-specific cell biology platforms with advanced gene editing techniques. Cibus focuses on creating plant traits that address specific agricultural challenges, including those related to productivity, disease resistance, insect control, weed management, nutrient use, and climate adaptability. Through these efforts, Cibus seeks to enhance the efficiency and sustainability of agricultural practices.

Founded in 2014, SenseTime specializes in artificial intelligence technologies, focusing on computer vision and deep learning. It offers a range of AI solutions including face and body analysis, image recognition, video comprehension, SLAM and 3D Vision, robot sensing, autonomous driving, medical image analysis, and AI supercomputing platforms. Serving sectors such as smart city, mobile, entertainment, automobile, health, business, education, and advertising worldwide, SenseTime operates offices in major cities across Asia.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Atom Tickets is a mobile and web platform that streamlines moviegoing by enabling users to find, reserve, and pay for movie tickets and concessions from Android and iOS devices. The app provides information on current films, including reviews, trailers, and synopses, and combines ticketing with social features that let users invite friends, share listings, and coordinate group seating. Customers can order snacks in advance and pay for tickets separately, reducing wait times at theaters. The platform supports planning and payment across devices, eliminates the need for paper tickets, and helps groups coordinate screenings and payments through integrated messaging and social sharing. Based in Santa Monica, California, Atom Tickets focuses on making the movie-going experience easier and more social by uniting ticket purchasing, concessions, and group arrangements in a single app and website.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company has a diverse pipeline of clinical-stage product candidates, including Rilonacept, which is undergoing Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, currently in Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Kiniksa also has preclinical candidates, such as KPL-404, which targets the CD40/CD40L interaction in immune responses. Additionally, the company is collaborating with Kite Pharma to explore the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa Pharmaceuticals aims to address multiple autoimmune and autoinflammatory conditions through its innovative approaches.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

Wheels Up is a membership-based private aviation company that specializes in on-demand flight services in the United States. By leveraging data and technology, it connects consumers with safety-vetted private aircraft, offering both programmatic and charter options. The company aims to reduce the upfront costs associated with private flying while providing flexibility, service, and safety to its members. Through its mobile app, users can easily book flights, manage accounts, and access ride-share opportunities. Additionally, members participate in the Wheels Down program, which enhances their travel experiences. Wheels Up operates a diverse fleet, utilizing owned, leased, and chartered aircraft to provide a wide range of global travel alternatives.

Reddit is an online platform that enables users to submit links, create content, and engage in discussions across topic-based communities known as subreddits. The site relies on user-generated content and volunteer moderators to manage conversations and enforce community guidelines. Users participate by posting, commenting, and voting, and can join or form communities around shared interests. Founded in 2005 by Steve Huffman and Alexis Ohanian, Reddit generates revenue primarily from advertising, premium memberships, and data licensing agreements.

Spring is a retail company that offers a diverse selection of products, including apparel and home and garden items. It operates as a shopping application designed for iOS devices, allowing users to follow their favorite brands and purchase new arrivals, exclusives, and unique products. Originally founded as Jello Labs, the company rebranded to Spring in July 2014. The founders of Spring are David Tisch, Alan Tisch, and Octavian Costache, and the company is based in New York.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its products include Chromium platforms for single-cell gene expression analysis, immune profiling, epigenetics study, and spatial gene expression measurement. Serving academic, government, biopharmaceutical, and other institutions globally.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Viridian Therapeutics is a biotechnology company dedicated to developing treatments for patients with underserved diseases. Its primary focus is on thyroid eye disease, a debilitating orphan condition, using product candidates such as Veligrotug.

Handy, founded in 2012, is an online platform that provides a reliable and convenient way for customers to book household services, including home cleaning, plumbing, and home renovations. Operating in the United States, Canada, and the United Kingdom, Handy allows users to schedule appointments with pre-approved, experienced, and background-checked professionals in just a few minutes. The platform has facilitated millions of bookings, serving over 500,000 customers and activating over 50,000 independent service providers. Handy aims to connect homeowners with a wide range of services, from routine cleanings to more complex tasks like major renovations. Customers can easily access these services through the Handy app or website, ensuring that their home maintenance needs are met efficiently and at a high standard. With a focus on customer satisfaction, Handy offers a guarantee to address any issues that may arise, reinforcing its commitment to providing a dependable and stress-free experience for homeowners.

Bracket Computing, based in Mountain View, California, develops software designed to enhance workload isolation and security for enterprises operating in hybrid cloud environments. The company's solution includes crypto-enforced micro-segmentation with always-on encryption of data at rest and in motion, utilizing customer-controlled keys. Additionally, it offers data and runtime integrity monitoring, along with auditability and forensic capabilities that capture memory during breaches. Founded in 2011, Bracket Computing aims to reimagine enterprise computing through radical innovation, providing a secure platform that empowers IT departments to maintain speed and agility while protecting against malware, malicious insiders, and operational errors.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Made.com Design Limited specializes in designing, manufacturing, and distributing high-end furniture, making luxury home design accessible to consumers. Founded in 2009 and based in London, the company connects customers directly with designers, eliminating middlemen to offer high-quality, made-to-order products at competitive prices. Made.com features a diverse range of furniture, including sofas, chairs, tables, lighting, storage solutions, and bedding, catering to various styles and needs. By selling exclusively online and avoiding showrooms and warehouses, the company minimizes waste and surplus stock, producing items in response to grouped customer orders every seven days. This approach enables Made.com to provide furniture typically priced 70-85% lower than traditional retailers. The brand collaborates with renowned designers and skilled craftsmen, ensuring quality while maintaining affordability. With a growing customer base, Made.com continues to transform the furniture market by offering stylish, well-crafted pieces that enhance home environments.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

PAX Labs, Inc. is a prominent manufacturer of loose-leaf vaporizers and accessories designed for dry herbs and concentrates. With a focus on innovation and premium design, PAX offers a range of products including the PAX 3, PAX 2, and PAX Era, alongside their related accessories. The company also provides an online mobile application to enhance user experience. Founded in 2004 and initially known as Ploom, Inc., PAX Labs rebranded in 2015 and has since established itself as a leader in the vaporization technology sector. Headquartered in San Francisco, California, PAX Labs distributes its products through a network of retailers and distributors in the United States and internationally, as well as via online platforms.

PAX Labs, Inc. is a prominent manufacturer of loose-leaf vaporizers and accessories designed for dry herbs and concentrates. With a focus on innovation and premium design, PAX offers a range of products including the PAX 3, PAX 2, and PAX Era, alongside their related accessories. The company also provides an online mobile application to enhance user experience. Founded in 2004 and initially known as Ploom, Inc., PAX Labs rebranded in 2015 and has since established itself as a leader in the vaporization technology sector. Headquartered in San Francisco, California, PAX Labs distributes its products through a network of retailers and distributors in the United States and internationally, as well as via online platforms.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Blue Bottle Coffee is a specialty coffee company that delivers fresh-roasted beans nationwide through subscriptions. With a global team of hundreds, they operate cafes in multiple cities and offer a range of brewing tools and merchandise.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Hootsuite is a social media management platform that assists businesses in engaging with their customers across various social media channels. The platform provides a comprehensive suite of tools designed to simplify marketing efforts, enhance sales, and improve customer service. Users can create, schedule, publish, and manage content and advertising campaigns from a single, secure web-based dashboard. Hootsuite's features enable organizations to manage all their social media profiles efficiently, discover effective content, and analyze trends through relevant data insights. This functionality helps businesses optimize their social media strategies and connect more effectively with their audiences.

Manthan is a leading cloud analytics company for consumer facing businesses. We excel in the application of decision sciences, advanced math and artificial intelligence and have a restless ability to invent and bring ideas to life. Manthan’s analytics solutions are powered by AI, cloud and prescriptive capabilities. They are unique in their ability to use machine intelligence to process every decision context and respond automatically with actions and recommendations to manage every aspect of a consumer business, whether its marketing, merchandising, channel/store, demand or supply. Manthan’s inventions aim to bring a new paradigm of context-aware, automated and algorithmic business decisions and actions, executed at scale.

Kobo is an e-reading platform that offers a wide range of digital content through its eBook store, with nearly 4 million titles available in 68 languages. Users can access this content on various devices using e-reader apps for Apple, BlackBerry, Android, and Windows platforms. Kobo also provides a seamless reading experience by allowing bookmarks to synchronize across devices. With a global reach spanning 190 countries and partnerships with 17,600 locations worldwide, Kobo has established itself as a leading digital reading provider since its founding in 2009, headquartered in Toronto, Ontario.

Zynga Inc., established in 2007, is a leading global developer, publisher, and operator of social games. The company's portfolio spans over 6 billion downloads across 175 countries, featuring popular franchises like FarmVille, Words With Friends, and Zynga Poker. Zynga's games are played on mobile platforms (iOS, Android) and social networking sites, with revenue generated through game downloads, in-game purchases, and advertising services. The company's headquarters are in San Francisco, California, with additional locations in North America, Europe, and Asia.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Exit41's Software as a Service (SaaS) social ordering solutions have processed over twenty million food orders for consumers on behalf of leading restaurant brands across the globe including Qdoba Mexican Grill, la Madeleine, Cara Operations, Americana Group and Lettuce Entertain You Enterprises. Exit41's web and mobile applications enable restaurants to connect with, recognize and reward their customers and build loyal, profitable relationships. Founded in 1999, Exit41 is headquartered in Andover, Massachusetts, and is backed by tier one investors including GrandBanks Capital and Dace Ventures.

Yipes is a data communications services provider. It was acquired in 2007 by Indian telecommunications service provider Reliance Communications. Yipes delivers scalable business-to-business and business-to-Internet IP networking services. Their regional IP network Yipes MAN seamlessly extends your company's LAN to other business locations or to business partner locations. Their Yipes NET Internet service brings the Web to your LAN at breakaway speeds. Yipes NET customers can also take advantage of Yipes' industry-leading security offering Yipes WALL managed firewall service, to safeguard their private information from the dangers of the public Internet. Yipes NAN replaces private line and frame relay services with the simplicity of Ethernet. Yipes WEB offers a full portfolio of Internet management services. Yipes TOUGH enables customers to extend the redundancy on their customer premise to the Yipes Network.

Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.